Targeting SLC5A2 suppresses colorectal tumour development by enhancing NK cell activity through extracellular vesicle-dependent MICA/B signalling
{{output}}
Tumour metabolic modulation represents a promising adjuvant therapeutic strategy for cancers, including colorectal cancer (CRC). Dapagliflozin, a clinically approved sodium‒glucose cotransporter 2 (SLC5A2/SGLT2) inhibitor, has attracted considerable attention... ...
